DUBLIN, May 13, 2016 /PRNewswire/ --
Dublin - Research and Markets has announced the addition of the "Global Renal Cell Carcinoma Drugs Market 2020" report to their offering.
The renal cell carcinoma drugs market is anticipated to cross US$ 4 Billion by 2020
ADCs - A Novel Treatment Option for RCC
Advancements in technology have helped in the development of novel drug molecules for the treatment of renal cell carcinoma. An example of one such type of drug molecules is ADCs. ADCs are monoclonal antibodies attached to biologically active drugs by chemical linkers with labile bonds. They allow sensitive discrimination between healthy and diseased tissue. Pharmaceutical companies are speeding up the development and commercialization of more of these ADCs as an alternative treatment option, which will help in the overall growth of renal cell carcinoma drug industry.
According to Global Renal Cell Carcinoma Drugs Market 2020 report recently, a group of scientists at Agensys Inc. developed a novel ADC by the name of AGS16F. Clinical trials are indicating that AGS16F inhibited tumor growth. AGS16F localized to tumors, formed the active metabolite Cys-mcMMAF, induced cell cycle arrest and apoptosis, and increased blood levels of caspase-cleaved cytokeratin-18, a marker of epithelial cell death. Similarly, Agensys Inc. is also developing another ADC for the treatment of clear cell RCC and papillary RCC. The ADC, AGS-16M8F/AGS-16C3F, is being developed with the help of ADC technology in-licensed from Seattle Genetics. AGS-16M8F is a fully human IgG2k monoclonal antibody, conjugated to microtubule disrupting agent MMAF via a plasma-stable linker, which bind to ENPP3. After successful completion and satisfactory results from the phase II trials, this compound will be transitioned to Astellas' development team who will conduct the Phase III studies and prepare and submit the NDA/BLA.
Another company, Seattle Genetics, is also developing a novel treatment option for renal cell carcinoma. This treatment option is by the name of SGN-CD70A. SGN-CD70A is a novel antibody-drug conjugate targeted to CD70 utilizing the company's newest ADC technology. This ADC is currently under phase I clinical trial which have been designed to assess its safety and antitumor activity in patients suffering from renal cell carcin
Key Topics Covered:
1. Analyst View
2. Research Methodology
3. Renal Cell Carcinoma - An Introduction
4. Drivers and Challenges
4.1.1 Increasing Geriatric Population
4.1.2 Quick Diagnosis with Modern Imaging Techniques
4.1.3 Increasing Risk from Lifestyle Related Factors
4.1.4 Grants and Tax Credits
4.2.1 High Cost
4.2.2 Lack of Disease History Awareness & Research Participants
4.2.3 Rising Patent Cliff
5. Renal Cell Carcinoma Drugs Market Overview
6. Major Branded Drugs
7. Market Segmentation By Geography
7.1 North America
8. Renal Cell Carcinoma Drugs Pipeline
9. Trends and Developments
9.1 Positive Outcomes from Clinical Trials Driving RCC Market
9.2 ADCs - A Novel Treatment Option for RCC
10. Mergers and Acquisitions
11. Competitive Landscape
12. Key Players Analysis
12.1 Pfizer Inc.
12.2 F.Hoffmann-La Roche AG
12.5 Bayer AG
12.6 Bristol-Myers Squibb
12.7 Merck & Co., Inc.
12.9 Eli Lilly & Co.
12.10 Amgen Inc.
For more information visit http://www.researchandmarkets.com/research/mm9kbl/global_renal_cell
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets